FDA accelerates approval process for generic biologics to reduce drug costs
TL;DR Summary
The FDA announced new measures to streamline the approval process for generic biological drugs, or biosimilars, aiming to reduce development costs and accelerate market entry, ultimately lowering drug prices and increasing access for Americans.
- FDA to streamline approvals for generic biological drugs in latest move targeting health costs CNN
- FDA plans to speed approvals of biosimilars Axios
- FDA to speed up approvals of generic biologic medicines as Trump targets high drug costs CNBC
- US set to speed up approval for some generic drugs in blow to Big Pharma Financial Times
- Watch live: RFK Jr., FDA chief give remarks on lowering drug prices The Hill
Reading Insights
Total Reads
0
Unique Readers
1
Time Saved
3 min
vs 3 min read
Condensed
94%
583 → 34 words
Want the full story? Read the original article
Read on CNN